Irhythm Holdings, Inc. · NASDAQ:IRTC
Irhythm — iRhythm Technologies — Investor Presentation (October 2024)
17 slides from Irhythm's investor presentation, Oct 10, 2024
Slide 1: iRhythm Technologies Shareholder Engagement Fall 2024
iRhythm Technologies Shareholder Engagement Fall 2024
Slide 2: Agenda for upcoming dialogue
2© 2024 iRhythm Technologies, Inc. BUSINESS OVERVIEW & YTD 2024 ACCOMPLISHMENTS CORPORATE GOVERNANCE & BOARD COMPOSITION Agenda for upcoming dialogue EXECUTIVE COMPENSATION SUSTAINABILITY & CORPORATE RESPONSIBILITY
Slide 3: Safe harbor statement
© 2024 iRhythm Technologies, Inc. 3 Safe harbor statement Certain data in this presentation was obtained from various external sources, and neither “iRhythm” or the “Company” nor its affiliates or representatives has verified such data with independent sources. Accordingly, neither the Company nor a
Slide 4: a $148.0 million Second quarter 2024 revenue 5+ million tests Target market opportunity across
a $148.0 million Second quarter 2024 revenue 5+ million tests Target market opportunity across prioritized EU and APAC countries* Data on file. iRhythm Technologies, August 2024. *See sources in appendix for ‘International opportunity represents $1+ billion TAM with 5+ million tests in prioritized c
Slide 5: Compelling investment thesis for long-term shareholder value creation
5© 2024 iRhythm Technologies, Inc. MARKET EXPANSION OPPORTUNITIES INNOVATION OPERATIONAL EFFICIENCY FOCUS IMPROVING FINANCIAL PROFILE Compelling investment thesis for long-term shareholder value creation Core US market penetration Greenfield specialist growth Primary care physician growth Channel ex
Slide 6: iRhythm on a journey to evolve and mature our corporate profile
6© 2024 iRhythm Technologies, Inc. iRhythm on a journey to evolve and mature our corporate profile B U S I N E S S O V E R V I E W BUSINESS MATURITY CORPORATE GOVERNANCE LEADERSHIP COMPOSITION PROGRESS TO DATE ✓ Reimbursement pathway settled ✓ Transition to profitability ✓ Expanding global reach ✓ M
Slide 7: 2024 accomplishments reflective of ongoing improvements within organization
© 2024 iRhythm Technologies, Inc. 7 2024 accomplishments reflective of ongoing improvements within organization to foster a commitment to excellence Expanded into four European countries Received Japanese PMDA approval Reached 1 million registrations for Zio® monitor in U.S. BRINGING INNOVATIVE PROD
Slide 8: iRhythm evolving amidst business transformation efforts and ongoing market challenges
8© 2024 iRhythm Technologies, Inc. iRhythm evolving amidst business transformation efforts and ongoing market challenges 2020 2021 2022 2023 Tackled the COVID-19 crisis with expanded home enrollment Leadership changes resultant from prior CEO retirement Navigated CMS reimbursement challenges in long
Slide 9: Board of Directors comprised of industry experts with broad disciplinary expertise
9© 2024 iRhythm Technologies, Inc. CATHLEEN NOEL BAIREY MERZ, M.D. Director RALPH SNYDERMAN, M.D. Director MOJDEH POUL Director Board of Directors comprised of industry experts with broad disciplinary expertise and diverse backgrounds BRUCE G. BODAKEN Director, Nominating and Corporate Governance Ch
Slide 10: Experienced, diverse board with balanced tenure and experience
10© 2024 iRhythm Technologies, Inc. Experienced, diverse board with balanced tenure and experience BALANCED DIRECTOR TENURE WITH REGULAR REFRESHMENT Two new director appointments in 2023 SIGNIFICANT EXPERIENCE ACROSS MULTIPLE DISCIPLINES Eight independent directors DIRECTOR DIVERSITY TO ENABLE STRON
Slide 11: Strong leadership appointments are leading transformational improvements at iRhythm
11© 2024 iRhythm Technologies, Inc. QUENTIN BLACKFORD President, CEO, & Director SARA BENDER SVP, Chief of Staff & Corporate Strategy MERVIN SMITH EVP, Business Operations JULIE RODDA SVP, Head of People & Culture Strong leadership appointments are leading transformational improvements at iRhythm PA
Slide 12: Executive compensation program design aims to attract and retain top talent
12© 2024 iRhythm Technologies, Inc. Executive compensation program design aims to attract and retain top talent, pay for performance, and align interests with shareholders KEY COMPENSATION PHILOSOPHY ROOTED IN FOUNDATIONAL PRINCIPLES TO DRIVE TRANSFORMATIONAL CHANGE • Attract and retain high-caliber
Slide 13: 2023 CEO target compensation
13© 2024 iRhythm Technologies, Inc. 2023 CEO TARGET COMPENSATION Base salary 9% Majority of executive annual compensation is variable and tied to iRhythm’s operational, financial, and share price performance E X E C U T I V E C O M P E N S A T I O N Short-term cash incentive 9% Long-term equity ince
Slide 14: Timing of 2023 special one-time grants in relation to proxy release
14© 2024 iRhythm Technologies, Inc. May 25, 2023 FDA sends iRhythm warning letter focused on Zio AT system and alleged nonconformities related to medical device reporting requirements and quality system requirements3 Timing of 2023 special one-time grants in relation to proxy release 1. iRhythm Tech
Slide 15: ESG report reflects our commitment to sustainable and responsible growth
15© 2024 iRhythm Technologies, Inc. April 2023 ESG report reflects our commitment to sustainable and responsible growth to deliver long-term value ENVIRONMENTAL SUSTAINABILIT Y BY DESIGN Innovative design enables safe, effective reuse of circuit boards Key environmental approaches include energy eff
Slide 16: Appendix
iIRHYTHM Appendix
Slide 17: Sources
© 2024 iRhythm Technologies, Inc. 17 Sources REFERENCE SOURCES International opportunity represents $1+ billion TAM with 5+ million tests in prioritized countries across EMEA and Asia Pacific UK: iRhythm estimate. • UK Office for National Statistics; Hospital Episode Statistics, NHS Digital, 2019-20
iRhythm Technologies — Investor Presentation (October 2024) on 6ix